AR093491A1 - Proteinas de captura de superficie celular recombinantes - Google Patents
Proteinas de captura de superficie celular recombinantesInfo
- Publication number
- AR093491A1 AR093491A1 ARP130104196A ARP130104196A AR093491A1 AR 093491 A1 AR093491 A1 AR 093491A1 AR P130104196 A ARP130104196 A AR P130104196A AR P130104196 A ARP130104196 A AR P130104196A AR 093491 A1 AR093491 A1 AR 093491A1
- Authority
- AR
- Argentina
- Prior art keywords
- proteins
- cell surface
- recombinant cell
- surface capture
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Las proteínas de captura de la superficie celular recombinantes y las moléculas de detección que son útiles para aislar y detectar las células que producen una proteína secretada de interés (POI) tal como ciertas proteínas heterodiméricas que tienen un dominio CH3 de inmunoglobulina y/o un dominio CH3 sustituido. La presente también se proporcionan proteínas de captura de la superficie celular recombinantes y las moléculas de detección que aíslan y detectan anticuerpos biespecíficos. La presente también proporciona proteínas de unión a antígenos recombinantes que son capaces de reconocer y unirse a las proteínas de interés que contienen un dominio CH3 con o sin sustituciones de aminoácidos en H95 e Y96 (IMGT).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261726040P | 2012-11-14 | 2012-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093491A1 true AR093491A1 (es) | 2015-06-10 |
Family
ID=49679651
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104196A AR093491A1 (es) | 2012-11-14 | 2013-11-14 | Proteinas de captura de superficie celular recombinantes |
ARP210100032A AR121002A2 (es) | 2012-11-14 | 2021-01-07 | Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100032A AR121002A2 (es) | 2012-11-14 | 2021-01-07 | Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica |
Country Status (20)
Country | Link |
---|---|
US (3) | US9758592B2 (es) |
EP (2) | EP2949667B1 (es) |
JP (2) | JP6668074B2 (es) |
KR (4) | KR20210014766A (es) |
CN (2) | CN109485728A (es) |
AR (2) | AR093491A1 (es) |
AU (3) | AU2013344769B2 (es) |
BR (1) | BR112015010758A2 (es) |
CA (2) | CA2889541C (es) |
DK (2) | DK2920208T3 (es) |
EA (2) | EA202190266A1 (es) |
ES (2) | ES2817373T3 (es) |
HK (2) | HK1211036A1 (es) |
IL (3) | IL238176B (es) |
MX (2) | MX2015006112A (es) |
PL (2) | PL2920208T3 (es) |
SG (2) | SG10201804124XA (es) |
TW (3) | TWI675044B (es) |
WO (1) | WO2014078475A2 (es) |
ZA (1) | ZA201502538B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
TWI675044B (zh) | 2012-11-14 | 2019-10-21 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
EA038931B9 (ru) * | 2014-11-20 | 2022-02-18 | Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. | Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений |
US10520511B2 (en) * | 2015-05-12 | 2019-12-31 | Regeneron Pharmaceuticals, Inc. | Multimeric protein purity determination |
EP3349791A1 (en) | 2015-09-15 | 2018-07-25 | Board of Regents, The University of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
SG10202010155YA (en) | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
BR112018071285A2 (pt) | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores, vetor, sistema, e, método |
IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
JP7287940B2 (ja) * | 2017-03-24 | 2023-06-06 | ランケナウ・インスティテュート・フォー・メディカル・リサーチ | ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物 |
CN107177613A (zh) * | 2017-07-18 | 2017-09-19 | 哈尔滨紫霞生物科技有限公司 | 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法 |
JP7425725B2 (ja) * | 2017-12-07 | 2024-01-31 | 中外製薬株式会社 | 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法 |
WO2020068631A1 (en) * | 2018-09-24 | 2020-04-02 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
US20220144916A1 (en) * | 2019-02-12 | 2022-05-12 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5151350A (en) * | 1982-10-27 | 1992-09-29 | Repligen Corporation | Cloned genes encoding recombinant protein a |
US5635354A (en) | 1991-01-09 | 1997-06-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system |
US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
US6399368B1 (en) | 1992-01-17 | 2002-06-04 | Board Of Regents, The University Of Texas System | Secretion of T cell receptor fragments from recombinant Escherichia coli cells |
ATE237808T1 (de) | 1992-10-21 | 2003-05-15 | Stefan Miltenyi | Direkte auswahl von zellen durch ein aussheidungsprodukt |
US6482655B1 (en) | 1993-07-23 | 2002-11-19 | University Of Utah Research Foundation | Immunoassay procedure utilizing fluorogenic tracer antigens |
US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6232066B1 (en) | 1997-12-19 | 2001-05-15 | Neogen, Inc. | High throughput assay system |
CA2330678C (en) | 1998-05-11 | 2009-04-07 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
KR100518958B1 (ko) | 1998-05-20 | 2005-10-06 | 추가이 세이야쿠 가부시키가이샤 | 신규한 유전자 클로닝 방법 |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
DE19900635A1 (de) | 1999-01-11 | 2000-07-13 | Deutsches Krebsforsch | Selektion von monoklonalen Antikörpern |
US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20090137416A1 (en) * | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
US20140072979A1 (en) | 2001-01-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
US20140072980A1 (en) | 2001-01-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
EP1998266A3 (en) | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
EP1438400B1 (en) | 2001-10-01 | 2009-06-17 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
CN101809037B (zh) * | 2007-07-31 | 2014-01-15 | 瑞泽恩制药公司 | 人cd20的人抗体及其使用方法 |
MX2011014008A (es) * | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
SI2522724T1 (sl) * | 2009-12-25 | 2020-07-31 | Chuqai Seiyaku Kabushiki Kaisha | Postopek za spremembo polipeptida za čiščenje polipetidnih multimerov |
TWI675044B (zh) | 2012-11-14 | 2019-10-21 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
-
2013
- 2013-11-13 TW TW102141304A patent/TWI675044B/zh active
- 2013-11-13 TW TW110138498A patent/TW202206465A/zh unknown
- 2013-11-13 TW TW107128129A patent/TWI745610B/zh active
- 2013-11-14 MX MX2015006112A patent/MX2015006112A/es active IP Right Grant
- 2013-11-14 KR KR1020217003226A patent/KR20210014766A/ko not_active IP Right Cessation
- 2013-11-14 CN CN201811342204.8A patent/CN109485728A/zh active Pending
- 2013-11-14 EP EP15172149.5A patent/EP2949667B1/en active Active
- 2013-11-14 SG SG10201804124XA patent/SG10201804124XA/en unknown
- 2013-11-14 ES ES13798483T patent/ES2817373T3/es active Active
- 2013-11-14 CA CA2889541A patent/CA2889541C/en active Active
- 2013-11-14 BR BR112015010758A patent/BR112015010758A2/pt not_active Application Discontinuation
- 2013-11-14 SG SG11201502629TA patent/SG11201502629TA/en unknown
- 2013-11-14 KR KR1020237026105A patent/KR20230119245A/ko not_active Application Discontinuation
- 2013-11-14 CN CN201380059198.4A patent/CN104797598B/zh active Active
- 2013-11-14 JP JP2015542760A patent/JP6668074B2/ja active Active
- 2013-11-14 US US14/079,686 patent/US9758592B2/en active Active
- 2013-11-14 DK DK13798483.7T patent/DK2920208T3/da active
- 2013-11-14 WO PCT/US2013/069993 patent/WO2014078475A2/en active Application Filing
- 2013-11-14 EP EP13798483.7A patent/EP2920208B1/en active Active
- 2013-11-14 CA CA3204343A patent/CA3204343A1/en active Pending
- 2013-11-14 DK DK15172149.5T patent/DK2949667T3/da active
- 2013-11-14 KR KR1020227004696A patent/KR102563030B1/ko active IP Right Grant
- 2013-11-14 AU AU2013344769A patent/AU2013344769B2/en active Active
- 2013-11-14 ES ES15172149T patent/ES2805526T3/es active Active
- 2013-11-14 PL PL13798483T patent/PL2920208T3/pl unknown
- 2013-11-14 EA EA202190266A patent/EA202190266A1/ru unknown
- 2013-11-14 AR ARP130104196A patent/AR093491A1/es active IP Right Grant
- 2013-11-14 EA EA201590928A patent/EA037546B1/ru unknown
- 2013-11-14 PL PL15172149T patent/PL2949667T3/pl unknown
- 2013-11-14 KR KR1020157014594A patent/KR20150084028A/ko active Application Filing
-
2015
- 2015-04-12 IL IL238176A patent/IL238176B/en active IP Right Grant
- 2015-04-15 ZA ZA2015/02538A patent/ZA201502538B/en unknown
- 2015-05-14 MX MX2019015887A patent/MX2019015887A/es unknown
- 2015-11-26 HK HK15111643.1A patent/HK1211036A1/xx unknown
-
2016
- 2016-03-07 HK HK16102584.0A patent/HK1214612A1/zh unknown
-
2017
- 2017-09-11 US US15/700,404 patent/US20180118852A1/en not_active Abandoned
-
2018
- 2018-09-20 JP JP2018175921A patent/JP6856593B2/ja active Active
- 2018-10-23 AU AU2018253474A patent/AU2018253474B2/en active Active
-
2020
- 2020-06-10 IL IL275270A patent/IL275270B/en unknown
- 2020-09-18 US US17/025,656 patent/US20210009714A1/en active Pending
-
2021
- 2021-01-07 AR ARP210100032A patent/AR121002A2/es unknown
- 2021-04-19 AU AU2021202371A patent/AU2021202371A1/en active Pending
- 2021-07-21 IL IL285015A patent/IL285015A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121002A2 (es) | Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
PH12016501212A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
DOP2014000029A (es) | Proteínas y péptidos modificados. | |
AR093984A1 (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano | |
DK2542590T4 (da) | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
EA202192126A2 (ru) | Способы сбора культур клеток млекопитающих | |
BR112015019614A2 (pt) | análise de imagens e medições de amostras biológicas | |
CR20120027A (es) | Polipeptidos y metodo de tratamiento | |
EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
IL222507B (en) | Proteins comprising heterodimeric antibody fc and methods for their preparation | |
FR2955743B1 (fr) | Confiseries aux proteines de pois | |
GB201111361D0 (en) | Biochemical markers for neurodegenerative conditions | |
IN2014CN02113A (es) | ||
BR112013013573A2 (pt) | método para produzir anticorpos específicos para um antígeno de interesse, célula b isolada ou recombinante, população de anticorpo, e, anticorpo | |
EA201592022A1 (ru) | Расщепляемый тромбином линкер, содержащий xten, и его применение | |
BR112015008036A2 (pt) | população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit | |
DK2547694T5 (da) | Hidtil ukendt signalpeptid og anvendelse deraf til fremstilling af rekombinante proteiner | |
EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
EA201400356A1 (ru) | Иммуноанализ для обнаружения антибиотиков | |
GB2541596A (en) | Method and composition for determining specific antibody responses to species of filovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |